Abstract
Lung cancer is the most common cancer with high mortality. Increasing evidence has demonstrated that nonstructural maintenance of chromosomes condensin I complex subunit G (NCAPG) plays a crucial role in the progression of human cancers. However, the biological function and underlying mechanism of NCAPG in non–small cell lung cancer (NSCLC) are still unclear. Here, we utilized diverse public databases to analyze the expression of NCAPG in pan-cancer. We found that NCAPG was highly expressed in various human cancers, especially in NSCLC. NCAPG expression was significantly positively correlated with poor clinical-pathological features, poor prognosis, tumor mutational burden, DNA microsatellite instability, and immune cell infiltration in NSCLC. In addition, our results showed that depletion of NCAPG significantly inhibited NSCLC cell proliferation, migration, and self-renewal abilities, yet these could be reversed by adding microRNA (miRNA)-214-3p. Knockdown of long noncoding RNA (lncRNA) thymidylate synthetase opposite strand (TYMSOS) also inhibits the NSCLC cell proliferation, migration, and self-renewal abilities. In summary, our findings demonstrated that the crucial roles of the FOXM1/lncRNA-TYMSOS/miRNA-214-3p/NCAPG axis in NSCLC may shed light on how NCAPG may act as a therapeutic target for NSCLC.
Highlights
Lung cancer is the major cause of cancer-related death worldwide, according to cancer statistics in 2020, the morbidity rate of lung cancer ranks second, whereas the death rate of lung cancer ranks the top (Siegel et al, 2020)
The results revealed that NCAPG was significantly up-regulated in 21 cancer types than normal samples, including bladder urothelial carcinoma, breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma (LUAD), lung squamous cell carcinoma, pheochromocytoma and paraganglioma, prostate adenocarcinoma, rectum adenocarcinoma, skin cutaneous melanoma, stomach adenocarcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma were prominently ascended when matched to normal tissues (Figure 1A)
The result showed that NCAPG expression in adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), colon adenocarcinoma (COAD), DLBC, esophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), LUAD, lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma, rectum adenocarcinoma, SKCM, stomach adenocarcinoma (STAD), THYM, uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS) was significantly elevated in cancer than corresponding normal controls
Summary
Lung cancer is the major cause of cancer-related death worldwide, according to cancer statistics in 2020, the morbidity rate of lung cancer ranks second, whereas the death rate of lung cancer ranks the top (Siegel et al, 2020). Studies have started to characterize the regulatory effects that condensin complexes may have on diverse cancers, including colon adenocarcinoma and liver hepatocellular carcinoma. These condensin complexes play a different role in the progression of cancer, as well as drug resistance (Wu et al, 2019). Its elevated expression has been reported in several cancers, including hepatocellular carcinoma (HCC) (Gong et al, 2019), gastric cancer (Sun et al, 2020), ovarian cancer (Xu et al, 2020b), and cardia adenocarcinoma (Zhang et al, 2021). Our study utilized various bioinformatics approaches and functional studies to examine whether NCAPG is involved in NSCLC progression, immune infiltration, and its plausible molecular regulation
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
